HOME > News Releases 2021 > Regarding the Recent Novel Coronavirus Infection at an ESPEC Subsidiary and its Subsidiary

Text Size
SML

Print

Regarding the Recent Novel Coronavirus Infection at ESPEC and its Subsidiary

Aug. 20, 2021

ESPEC Corporation has confirmed one person at the Fukuchiyama Plant, two people at the Nagoya Sales Office, and one person at ESPEC MIC CORP. (an ESPEC subsidiary) as having become infected with the novel coronavirus.
The employee at the Fukuchiyama Plant reported a fever on Tuesday, August 17, and underwent a PCR test the same day, which came back positive. The employee will be recuperating at home for the foreseeable future. Meanwhile, one employee at the Nagoya Sales Office reported a fever on Wednesday, August 11, and underwent a PCR test on Saturday, August 14, which came back positive the following day. The employee will be recuperating at home for the foreseeable future. The Public Health Center has confirmed that no one within any of these two ESPEC locations has come into close contact with these individuals.
Another employee at the Nagoya Sales Office reported a fever on Sunday, August 15, and underwent a PCR test the following day, which came back positive on Tuesday, August 17. The employee will be recuperating at home for the foreseeable future. The employee at ESPEC MIC reported a fever on Wednesday, August 18, and underwent a PCR test the same day, which came back positive. The employee will be recuperating at home for the foreseeable future. Although ESPEC is still waiting on official results from the Public Health Center, an in-house investigation has determined that no one has come into close contact with these two individuals, and no other employees at these two locations have reported any fever or other symptoms. ESPEC will take the appropriate measures should the Public Health Center report anyone from or in any way related to ESPEC has been significantly exposed.
We apologize for any concern that may have been caused to local residents and to everyone else involved.
ESPEC will continue to take appropriate infection control measures based on the policies of the federal and local governments.

Contact Details:

Corporate Communication Department ESPEC CORP.

TEL:06-6358-4744 FAX:06-6358-4795
E-MAIL:ir-div@espec.jp